<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Ruff, Christian T.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">ENGAGE AF-TIMI 48: Tailoring Edoxaban Dose Preserves Drug Efficacy and Safety</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">25-27</style></pages><abstract><style  face="normal" font="default" size="100%">The Effective Anticoagulation With Factor Xa Next Generation in the Atrial Fibrillation—TIMI 48 trial [ENGAGE AF-TIMI 48; Giugliano RP et al. N Engl J Med. 2013] of 21?105 patients with atrial fibrillation and CHADS2 scores =?2 reported the noninferiority of the oral factor Xa inhibitor edoxaban 30 and 60 mg once daily versus warfarin and dose-related decreases in major bleeding. This article presents the results of a subanalysis showing that the protocol-driven dose adjustments in ENGAGE AF maintained the efficacy of edoxaban and reduced bleeding.</style></abstract><number><style face="normal" font="default" size="100%">27</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>